Pharmaceutical company files IND application with FDA for glaucoma candidate
September 08, 2021
TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Glaucoma Insights
MIGS with OMNI system linked with diminished diurnal IOP fluctuations, a risk factor for glaucoma progression
November 17, 2021
The 12-Month OMNI data from the prospective, multicenter GEMINI clinical trial show statistically significant postoperative reductions in mean IOP and suppression of daily IOP fluctuations.
Study highlights favorable two-year outcomes of standalone use of surgical system on mild to moderate open-angle glaucoma
August 24, 2021
Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.
Study: Gene therapy could preserve vision in patients with retinal disease, serious retinal injury
July 28, 2021
Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.
FDA grants Investigational Device Exemption for MINIject in glaucoma patients
July 15, 2021
According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.
Studying glaucoma epidemiology at the center of the Earth
January 30, 2021
Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.
Effect of Open-Angle Glaucoma Medications on Ocular Surface
February 17, 2020
MIGS Surgery to Manage Non-Adherence in Open-Angle Glaucoma
February 10, 2020
Importance of Adherence in Treatment of Open-Angle Glaucoma
February 10, 2020
Targeting MMP to Treat Open-Angle Glaucoma
February 03, 2020